WA-T-MOBILE
20.9.2022 09:31:02 CEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that ICE Cobotics, a global leader in cleaning technologies and equipment, has chosen T IoT as its exclusive IoT connectivity solution worldwide to help their customers more easily manage fleets of floor cleaning robots.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005555/en/
Floor cleaning and technology company picks T IoT to power i-SYNERGY fleet management software and strengthen its global subscription service (Photo: Business Wire)
As part of the long-term agreement, T IoT — a comprehensive solution for global IoT connectivity, platform management and support — will deliver cellular connectivity to more than 7,500 new and existing ICE Cobotics intelligent and autonomous cleaning units across the world. This includes their newest product, Cobi 18, a compact autonomous floor scrubber which is designed to clean 5,000 to 7,000 square feet per hour, starting at less than $20 a day.
ICE Cobotics chose T IoT to simplify the delivery and execution of IoT solutions on a global scale, which bolsters their mission to streamline processes for its customers. Less than a year ago, the company launched an industry first: an all-inclusive subscription service for floor cleaning machines, parts and maintenance, and performance and monitoring software. The service provides customers with a more reliable, affordable, and cost predictive solution, allowing them to use their capital to expand their business versus having it tied up in equipment ownership.
T IoT supports ICE Cobotics’ subscription model by delivering cleaning performance data and insights to customers in the retail, grocery, convenience, healthcare, higher education, and hospitality industries. Imagine a major retail corporation that has hundreds of robots in service. The cellular connectivity allows a customer’s maintenance and facilities team to view their Clean Score — goal-based cleaning performance data generated by ICE Cobotics’ i-SYNERGY fleet management software. This takes the guess work out of tracking cleaning efficacy, developing efficiencies, and confirming each location is clean. Previously, they would have had to visit each store to inspect if cleaning happened, which takes time and money.
Additionally, T IoT reinforces ICE Cobotics’ commitment to eliminate downtime by delivering over the air software and firmware updates to its customers, as well as mechanical telemetry data, from sensors and cameras in each machine, back to the company. This gives them the ability to monitor and analyze critical information like hours of use, routes, temperature, and battery life — so they can determine if certain components of a machine are operating within tolerance, if service is required and if a part is near its end of life — to prevent problems before they happen.
“T IoT is critical to the success of our cleaning machines and our all-inclusive subscription service,” said Mike DeBoer, President, ICE Cobotics U.S. “The data we receive from our autonomous scrubbers allows us to deliver cleaning performance insights and an enhanced clean to our customers at an affordable price.”
“This is what T IoT was designed for — helping enterprises solve global IoT challenges and deliver innovative solutions that make their customers want more,” said Callie Field, President, T-Mobile Business Group. “Like ICE Cobotics, T-Mobile and Deutsche Telekom share a passion for the pursuit of simple and we salute their ongoing mission to make things easier for their customers.”
To learn more about ICE Cobotics, visit www.us.icecobotics.com.
For more information about T IoT, visit www.t-mobile.com/business/solutions/iot/t-iot-global.
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
About T-Mobile
T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom